Selecta Biosciences Inc Headquarters
Looking for information about Selecta Biosciences Inc Headquarters? The links below have collected all the necessary data.
Contact - Selecta Biosciences
- https://selectabio.com/contact/
- Selecta Biosciences, Inc. 65 Grove Street Watertown, MA 02472. 617-923-1400
Home - Selecta Biosciences
- https://selectabio.com/
- Selecta Biosciences is a clinical-stage biotechnology company with an unrelenting commitment to overcoming immunogenicity with our pioneering ImmTOR™ immune tolerance platform. Our Platform.
Selecta Biosciences Company Profile - Office Locations ...
- https://craft.co/selecta-biosciences
- Jun 01, 2021 · Selecta Biosciences has 39 employees at their 1 location and $16.6 M in annual revenue in FY 2020. See insights on Selecta Biosciences including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.Employees: 39
Selecta Biosciences - Crunchbase Company Profile & Funding
- https://www.crunchbase.com/organization/selecta-biosciences
- Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles.Founded: 2008
Selecta Biosciences Company Profile: Stock Performance ...
- https://pitchbook.com/profiles/company/51604-12
- Selecta Biosciences Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency ...
Selecta Biosciences LinkedIn
- https://www.linkedin.com/company/selecta-bio
- Selecta Biosciences 1,554 followers on LinkedIn. Leveraging clinically validated ImmTOR™ platform to develop tolerogenic therapies. Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its ...
Investor Overview Selecta Biosciences Inc
- https://selectabio.gcs-web.com/
- Aug 12, 2021 · Selecta Biosciences Inc. founded in 2008, is leveraging its clinically-validated ImmTOR TM platform to develop antigen-specific tolerogenic therapies. With a proven ability to induce tolerance to highly immunogenic molecules, ImmTOR can be leveraged to both amplify the efficacy of biologics, including redosing of life-saving gene therapies, as well as restore the body’s natural self ...
Selecta Biotech SE
- https://selectabiotech.com/
- The Diagnostics Division of Selecta Biotech focuses on R&D of a portfolio of qPCR mixes within the ampliTune® product line for early and precise detection of biomarkers with an exceptional sensitivity. The Division also provides consulting services to clients and offers strategic partnership to biotech and pharma companies to benefit from the ...
Selecta and AskBio Initiate First-in-Human Dose-Escalation ...
- https://www.askbio.com/selecta-and-askbio-initiate-first-in-human-dose-escalation-study-to-evaluate-immtor-in-gene-therapy/
- Feb 17, 2021 · Selecta and AskBio expect to report initial results from this clinical trial in the fourth quarter of 2021. About Selecta Biosciences, Inc. Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses.
Have you found Selecta Biosciences Inc Headquarters information?
On our site you can find many other information about headquarters of any company. Research information about other companies.